{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:34:08Z","timestamp":1792096448633,"version":"4.4.0"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LQ20C050002"],"award-info":[{"award-number":["LQ20C050002"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004863","name":"Zhejiang Chinese Medical University","doi-asserted-by":"publisher","award":["2019ZR09"],"award-info":[{"award-number":["2019ZR09"]}],"id":[{"id":"10.13039\/501100004863","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973571"],"award-info":[{"award-number":["81973571"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.bcp.2022.115279","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T11:51:42Z","timestamp":1665057102000},"page":"115279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges"],"prefix":"10.1016","volume":"205","author":[{"given":"Xiaoying","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanlin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luping","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2022.115279_b0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.biochi.2020.09.018","article-title":"The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2","volume":"179","author":"Muralidar","year":"2020","journal-title":"Biochimie"},{"issue":"7798","key":"10.1016\/j.bcp.2022.115279_b0010","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.bcp.2022.115279_b0015","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1016\/j.cell.2021.05.031","article-title":"Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species","volume":"184","author":"Liu","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2022.115279_b0020","doi-asserted-by":"crossref","unstructured":"R. Arya, S. Kumari, B. Pandey, H. Mistry, S.C. Bihani, A. Das, et al., Structural insights into SARS-CoV-2 proteins, J. Mol. Biol. 433(2) (2021) 166725.","DOI":"10.1016\/j.jmb.2020.11.024"},{"key":"10.1016\/j.bcp.2022.115279_b0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbrc.2020.08.116","article-title":"RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19","volume":"538","author":"Jiang","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.bcp.2022.115279_b0030","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/jmv.27588","article-title":"Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines","volume":"94","author":"Araf","year":"2022","journal-title":"J. Med. Virol."},{"issue":"7898","key":"10.1016\/j.bcp.2022.115279_b0035","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2022.115279_b0040","doi-asserted-by":"crossref","unstructured":"Q. Peng, R. Peng, B. Yuan, J. Zhao, M. Wang, X. Wang, et al., Structural and Biochemical Characterization of the nsp12-nsp7-nsp8 Core Polymerase Complex from SARS-CoV-2, Cell Rep. 31(11) (2020) 107774.","DOI":"10.1016\/j.celrep.2020.107774"},{"issue":"37","key":"10.1016\/j.bcp.2022.115279_b0045","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1323705111","article-title":"One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities","volume":"111","author":"Subissi","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bcp.2022.115279_b0050","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cell.2020.11.016","article-title":"Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription Complex Reveals an Intermediate State in Cap Synthesis","volume":"184","author":"Yan","year":"2021","journal-title":"Cell"},{"issue":"6498","key":"10.1016\/j.bcp.2022.115279_b0055","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","volume":"368","author":"Yin","year":"2020","journal-title":"Science"},{"issue":"6492","key":"10.1016\/j.bcp.2022.115279_b0060","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao","year":"2020","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bcp.2022.115279_b0065","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cell.2020.05.034","article-title":"Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"issue":"7819","key":"10.1016\/j.bcp.2022.115279_b0070","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41586-020-2368-8","article-title":"Structure of replicating SARS-CoV-2 polymerase","volume":"584","author":"Hillen","year":"2020","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bcp.2022.115279_b0075","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1021\/acs.jmedchem.0c01140","article-title":"Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities","volume":"65","author":"Cannalire","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2022.115279_b0080","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.bbrc.2020.11.043","article-title":"Remdesivir: From Ebola to COVID-19","volume":"538","author":"Santoro","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2022.115279_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104541","article-title":"Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase","volume":"169","author":"Brown","year":"2019","journal-title":"Antiviral Res."},{"issue":"5","key":"10.1016\/j.bcp.2022.115279_b0090","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2022.115279_b0095","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev-pharmtox-010716-105055","article-title":"Will There Be a Cure for Ebola?","volume":"57","author":"Cardile","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"3","key":"10.1016\/j.bcp.2022.115279_b0100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"issue":"12","key":"10.1016\/j.bcp.2022.115279_b0105","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","volume":"117","author":"de Wit","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7824","key":"10.1016\/j.bcp.2022.115279_b0110","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2","volume":"585","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2022.115279_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100794","article-title":"An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment","volume":"59","author":"Dro\u017cd\u017cal","year":"2021","journal-title":"Drug Resist Updat."},{"issue":"5","key":"10.1016\/j.bcp.2022.115279_b0120","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Cent. Sci."},{"issue":"19","key":"10.1016\/j.bcp.2022.115279_b0125","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19 - Final Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med."},{"issue":"13","key":"10.1016\/j.bcp.2022.115279_b0130","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-020-01378-w","article-title":"Remdesivir: First Approval","volume":"80","author":"Lamb","year":"2020","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.bcp.2022.115279_b0135","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20542-0","article-title":"Mechanism of SARS-CoV-2 polymerase stalling by remdesivir","volume":"12","author":"Kokic","year":"2021","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.bcp.2022.115279_b0140","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"MBio"},{"issue":"15","key":"10.1016\/j.bcp.2022.115279_b0145","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1074\/jbc.AC120.013056","article-title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus","volume":"295","author":"Gordon","year":"2020","journal-title":"J Biol Chem."},{"issue":"20","key":"10.1016\/j.bcp.2022.115279_b0150","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J Biol Chem."},{"issue":"47","key":"10.1016\/j.bcp.2022.115279_b0155","doi-asserted-by":"crossref","first-page":"16156","DOI":"10.1074\/jbc.AC120.015720","article-title":"Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action","volume":"295","author":"Tchesnokov","year":"2020","journal-title":"J Biol Chem."},{"key":"10.1016\/j.bcp.2022.115279_b0160","doi-asserted-by":"crossref","unstructured":"J. Wu, H. Wang, Q. Liu, R. Li, Y. Gao, X. Fang, et al., Remdesivir overcomes the S861 roadblock in SARS-CoV-2 polymerase elongation complex, Cell Rep. 37(4) (2021) 109882.","DOI":"10.1016\/j.celrep.2021.109882"},{"key":"10.1016\/j.bcp.2022.115279_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2022.115279_b0170","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/cbic.202000595","article-title":"Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options","volume":"22","author":"Sreekanth Reddy","year":"2021","journal-title":"Chembiochem."},{"issue":"5","key":"10.1016\/j.bcp.2022.115279_b0175","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jinf.2020.12.005","article-title":"Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients","volume":"82","author":"Chen","year":"2021","journal-title":"J Infect."},{"issue":"2","key":"10.1016\/j.bcp.2022.115279_b0180","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/jmv.26488","article-title":"Tolerability of favipiravir therapy in critically ill patients with COVID-19: A report of four cases","volume":"93","author":"Dauby","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.bcp.2022.115279_b0185","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijid.2020.11.142","article-title":"Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial","volume":"103","author":"Udwadia","year":"2021","journal-title":"Int J Infect Dis."},{"issue":"7","key":"10.1016\/j.bcp.2022.115279_b0190","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2021946118","article-title":"Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP","volume":"118","author":"Naydenova","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bcp.2022.115279_b0195","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-020-18463-z","article-title":"Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis","volume":"11","author":"Shannon","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2022.115279_b0200","article-title":"Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir","volume":"2","author":"Peng","year":"2021","journal-title":"Innovation (Cambridge (Mass.))"},{"issue":"8","key":"10.1016\/j.bcp.2022.115279_b0205","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/14787210.2021.1866545","article-title":"A review on favipiravir: the properties, function, and usefulness to treat COVID-19","volume":"19","author":"Hashemian","year":"2021","journal-title":"Expert Rev Anti Infect Ther."},{"key":"10.1016\/j.bcp.2022.115279_b0210","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","article-title":"Favipiravir as a potential countermeasure against neglected and emerging RNA viruses","volume":"153","author":"Delang","year":"2018","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/j.bcp.2022.115279_b0215","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/dmp.2014.151","article-title":"Favipiravir: a new medication for the Ebola virus disease pandemic","volume":"9","author":"Nagata","year":"2015","journal-title":"Disaster Med. Public Health Prep."},{"issue":"3","key":"10.1016\/j.bcp.2022.115279_b0220","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1055\/a-1296-7935","article-title":"Favipiravir and COVID-19: A Simplified Summary","volume":"71","author":"Ghasemnejad Berenji","year":"2021","journal-title":"Drug Res."},{"issue":"4","key":"10.1016\/j.bcp.2022.115279_b0225","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/13543776.2021.1880568","article-title":"SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19","volume":"31","author":"Vicenti","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"issue":"1","key":"10.1016\/j.bcp.2022.115279_b0230","doi-asserted-by":"crossref","first-page":"e00909","DOI":"10.1002\/prp2.909","article-title":"Molnupiravir: A new candidate for COVID-19 treatment","volume":"10","author":"Pourkarim","year":"2022","journal-title":"Pharmacol. Res. Perspect."},{"issue":"7850","key":"10.1016\/j.bcp.2022.115279_b0235","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","article-title":"SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801","volume":"591","author":"Wahl","year":"2021","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bcp.2022.115279_b0240","doi-asserted-by":"crossref","first-page":"e01965","DOI":"10.1128\/JVI.01965-17","article-title":"\u03b2-d- -Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome","volume":"92","author":"Urakova","year":"2018","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.bcp.2022.115279_b0245","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jiab247","article-title":"\u03b2-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells","volume":"224","author":"Zhou","year":"2021","journal-title":"J Infect Dis."},{"issue":"1","key":"10.1016\/j.bcp.2022.115279_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101992","article-title":"High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance","volume":"24","author":"Padhi","year":"2021","journal-title":"IScience"},{"issue":"6","key":"10.1016\/j.bcp.2022.115279_b0255","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med."},{"key":"10.1016\/j.bcp.2022.115279_b0260","article-title":"Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ (Clinical Research ed.)"},{"issue":"6","key":"10.1016\/j.bcp.2022.115279_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2021.102329","article-title":"Molnupiravir in COVID-19: A systematic review of literature","volume":"15","author":"Singh","year":"2021","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.bcp.2022.115279_b0270","doi-asserted-by":"crossref","first-page":"e935952","DOI":"10.12659\/MSM.935952","article-title":"Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients","volume":"28","author":"Parums","year":"2022","journal-title":"Med Sci Monit."},{"issue":"5","key":"10.1016\/j.bcp.2022.115279_b0275","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02428-20","article-title":"Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2","volume":"65","author":"Painter","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"24","key":"10.1016\/j.bcp.2022.115279_b0280","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01348-19","article-title":"Small-Molecule Antiviral \u03b2-d- -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance","volume":"93","author":"Agostini","year":"2019","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115279_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100770","article-title":"Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template","volume":"297","author":"Gordon","year":"2021","journal-title":"J Biol Chem."},{"issue":"9","key":"10.1016\/j.bcp.2022.115279_b0290","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"7496","key":"10.1016\/j.bcp.2022.115279_b0295","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2022.115279_b0300","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12967-020-02439-0","article-title":"Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach","volume":"18","author":"Aftab","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bcp.2022.115279_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2022.115279_b0310","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.antiviral.2016.11.003","article-title":"Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model","volume":"137","author":"Julander","year":"2017","journal-title":"Antiviral Res."},{"issue":"3","key":"10.1016\/j.bcp.2022.115279_b0315","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jiph.2016.04.002","article-title":"BCX4430 - A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease","volume":"9","author":"Taylor","year":"2016","journal-title":"J Infect Public Health."},{"issue":"1","key":"10.1016\/j.bcp.2022.115279_b0320","doi-asserted-by":"crossref","DOI":"10.3390\/v14010008","article-title":"Activity of Galidesivir in a Hamster Model of SARS-CoV-2","volume":"14","author":"Taylor","year":"2021","journal-title":"Viruses"},{"issue":"4050","key":"10.1016\/j.bcp.2022.115279_b0325","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1126\/science.177.4050.705","article-title":"Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide","volume":"177","author":"Sidwell","year":"1972","journal-title":"Science (New York, N.Y.)"},{"issue":"12","key":"10.1016\/j.bcp.2022.115279_b0330","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/82191","article-title":"The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen","volume":"6","author":"Crotty","year":"2000","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bcp.2022.115279_b0335","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1718806115","article-title":"Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA","volume":"115","author":"Ferron","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.bcp.2022.115279_b0340","first-page":"3204","article-title":"SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an perspective","volume":"39","author":"Elfiky","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bcp.2022.115279_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117477","article-title":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19","volume":"248","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2022.115279_b0350","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.2147\/IDR.S330743","article-title":"Ribavirin Treatment for Critically Ill COVID-19 Patients: An Observational Study","volume":"14","author":"Xu","year":"2021","journal-title":"Infect. Drug Resist."},{"issue":"10238","key":"10.1016\/j.bcp.2022.115279_b0355","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.bcp.2022.115279_b0360","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3851\/IMP1609","article-title":"Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy","volume":"15","author":"Brochot","year":"2010","journal-title":"Antivir. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2022.115279_b0365","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40265-018-0895-5","article-title":"Sofosbuvir\/Velpatasvir\/Voxilaprevir: A Review in Chronic Hepatitis C","volume":"78","author":"Heo","year":"2018","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.bcp.2022.115279_b0370","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1060028015610342","article-title":"Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection","volume":"50","author":"Smith","year":"2016","journal-title":"Ann Pharmacother."},{"key":"10.1016\/j.bcp.2022.115279_b0375","doi-asserted-by":"crossref","unstructured":"C.Q. Sacramento, N. Fintelman-Rodrigues, J.R. Temerozo, A.d.P.D. Da Silva, S.d.S.G. Dias, C.D.S. da Silva, et al., In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19, J Antimicrob Chemother.76(7) (2021) 1874\u20131885.","DOI":"10.1093\/jac\/dkab072"},{"issue":"11","key":"10.1016\/j.bcp.2022.115279_b0380","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1093\/jac\/dkaa334","article-title":"Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial","volume":"75","author":"Sadeghi","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"issue":"11","key":"10.1016\/j.bcp.2022.115279_b0385","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1021\/acs.jproteome.0c00392","article-title":"Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19","volume":"19","author":"Chien","year":"2020","journal-title":"J. Proteome Res."},{"issue":"29","key":"10.1016\/j.bcp.2022.115279_b0390","doi-asserted-by":"crossref","first-page":"18356","DOI":"10.1021\/acsomega.0c02096","article-title":"Prediction of Small Molecule Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus-2 RNA-dependent RNA Polymerase","volume":"5","author":"Ahmad","year":"2020","journal-title":"ACS Omega."},{"issue":"1","key":"10.1016\/j.bcp.2022.115279_b0395","doi-asserted-by":"crossref","first-page":"16577","DOI":"10.1038\/s41598-020-73641-9","article-title":"Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir","volume":"10","author":"Jockusch","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2022.115279_b0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2016.04.015","article-title":"Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)","volume":"119","author":"De Clercq","year":"2016","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115279_b0405","first-page":"33","article-title":"Advances in Nucleotide Antiviral Development from Scientific Discovery to Clinical Applications: Tenofovir Disoproxil Fumarate for Hepatitis B","volume":"1","author":"Lou","year":"2013","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.bcp.2022.115279_b0410","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1742-4690-6-44","article-title":"The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study","volume":"6","author":"Feng","year":"2009","journal-title":"Retrovirology"},{"key":"10.1016\/j.bcp.2022.115279_b0415","doi-asserted-by":"crossref","unstructured":"J. J. Parienti, T. Prazuck, L. Peyro Saint Paul, A. Fournier, C. Valentin, S. Brucato, et al., Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial, EClinicalMedicine. 38 (2021) 100993.","DOI":"10.1016\/j.eclinm.2021.100993"},{"issue":"13","key":"10.1016\/j.bcp.2022.115279_b0420","first-page":"4212","article-title":"The Nucleoside\/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2, Molecules (Basel","volume":"27","author":"Feng","year":"2022","journal-title":"Switzerland)"},{"key":"10.1016\/j.bcp.2022.115279_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2022.115279_b0430","doi-asserted-by":"crossref","unstructured":"I. Zanella, D. Zizioli, F. Castelli, E. Quiros-Roldan, Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection, Pharmaceuticals (Basel) 14(5) (2021) 454.","DOI":"10.3390\/ph14050454"},{"issue":"11","key":"10.1016\/j.bcp.2022.115279_b0435","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41422-021-00570-1","article-title":"Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2","volume":"31","author":"Xie","year":"2021","journal-title":"Cell Res."},{"issue":"32","key":"10.1016\/j.bcp.2022.115279_b0440","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.2174\/1568026621666210728094019","article-title":"Advancement of Prodrug Approaches for Nucleotide Antiviral Agents","volume":"21","author":"Li","year":"2021","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bcp.2022.115279_b0445","article-title":"Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects","volume":"1\u20139","author":"Qian","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.bcp.2022.115279_b0450","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1080\/22221751.2022.2078230","article-title":"An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants","volume":"11","author":"Shen","year":"2022","journal-title":"Emergi. Microbes Infect."},{"issue":"8","key":"10.1016\/j.bcp.2022.115279_b0455","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1021\/acs.jmedchem.1c00071","article-title":"Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine -Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV","volume":"64","author":"Mackman","year":"2021","journal-title":"J. Med. Chem."},{"issue":"643","key":"10.1016\/j.bcp.2022.115279_b0460","doi-asserted-by":"crossref","first-page":"eabm3410","DOI":"10.1126\/scitranslmed.abm3410","article-title":"Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice","volume":"14","author":"Sch\u00e4fer","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.bcp.2022.115279_b0465","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.1038\/s41467-021-26760-4","article-title":"Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets","volume":"12","author":"Cox","year":"2021","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bcp.2022.115279_b0470","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02479-20","article-title":"AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 and a Promising Oral Antiviral for Treatment of COVID-19","volume":"65","author":"Good","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2022.115279_b0475","doi-asserted-by":"crossref","unstructured":"C.B. Dousson, Current and future use of nucleo(s)tide prodrugs in the treatment of hepatitis C virus infection, Antivir Chem Chemother. 26 (2018) 2040206618756430.","DOI":"10.1177\/2040206618756430"},{"issue":"3","key":"10.1016\/j.bcp.2022.115279_b0480","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.7150\/thno.48342","article-title":"Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials","volume":"11","author":"Han","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.bcp.2022.115279_b0485","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41467-022-28113-1","article-title":"A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase","volume":"13","author":"Shannon","year":"2022","journal-title":"Nat. Commun."},{"issue":"30","key":"10.1016\/j.bcp.2022.115279_b0490","doi-asserted-by":"crossref","first-page":"9436","DOI":"10.1073\/pnas.1508686112","article-title":"Structural basis and functional analysis of the SARS coronavirus nsp14-nsp10 complex","volume":"112","author":"Ma","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.bcp.2022.115279_b0495","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1021\/jm201384j","article-title":"Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase","volume":"55","author":"Sofia","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2022.115279_b0500","first-page":"1","article-title":"Plant-Derived Natural Non-Nucleoside Analog Inhibitors (NNAIs) against Complex (nsp7\/nsp8\/nsp12) of SARS-CoV-2","author":"Naidu","year":"2021","journal-title":"J. Diet. Suppl."},{"issue":"3","key":"10.1016\/j.bcp.2022.115279_b0505","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01168-19","article-title":"100 Years of Suramin","volume":"64","author":"Wiedemar","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.bcp.2022.115279_b0510","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3390\/v12030314","article-title":"Suramin Inhibits Chikungunya Virus Replication by Interacting with Virions and Blocking the Early Steps of Infection","volume":"12","author":"Albulescu","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.bcp.2022.115279_b0515","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.antiviral.2017.04.016","article-title":"Suramin inhibits Zika virus replication by interfering with virus attachment and release of infectious particles","volume":"143","author":"Albulescu","year":"2017","journal-title":"Antiviral Res."},{"issue":"8","key":"10.1016\/j.bcp.2022.115279_b0520","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00900-20","article-title":"Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle","volume":"64","author":"Salgado-Benvindo","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.bcp.2022.115279_b0525","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41594-021-00570-0","article-title":"Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin","volume":"28","author":"Yin","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"13","key":"10.1016\/j.bcp.2022.115279_b0530","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1042\/BCJ20210200","article-title":"Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp12\/7\/8 RNA-dependent RNA polymerase","volume":"478","author":"Bertolin","year":"2021","journal-title":"Biochem J."},{"issue":"14","key":"10.1016\/j.bcp.2022.115279_b0535","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1601089113","article-title":"Suramin inhibits cullin-RING E3 ubiquitin ligases","volume":"113","author":"Wu","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.bcp.2022.115279_b0540","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3390\/v13050873","article-title":"The Repurposed Drugs Suramin and Quinacrine Cooperatively Inhibit SARS-CoV-2 3CL In Vitro","volume":"13","author":"Eberle","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.bcp.2022.115279_b0545","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12985-016-0607-2","article-title":"Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry","volume":"13","author":"Hen\u00df","year":"2016","journal-title":"Virol J."},{"issue":"4","key":"10.1016\/j.bcp.2022.115279_b0550","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1200\/JCO.1989.7.4.499","article-title":"Suramin: an anticancer drug with a unique mechanism of action","volume":"7","author":"Stein","year":"1989","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bcp.2022.115279_b0555","doi-asserted-by":"crossref","unstructured":"L.D. Kaplan, P.R. Wolfe, P.A. Volberding, P. Feorino, J.A. Levy, D.I. Abrams, et al., Lack of response to suramin in patients with AIDS and AIDS-related complex, Am J Med. 82(3 Spec No) (1987) 615\u2013620.","DOI":"10.1016\/0002-9343(87)90108-2"},{"key":"10.1016\/j.bcp.2022.115279_b0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115973","article-title":"A comprehensive review on the biological interest of quinoline and its derivatives","volume":"32","author":"Matada","year":"2021","journal-title":"Biorg. Med. Chem."},{"key":"10.1016\/j.bcp.2022.115279_b0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114576","article-title":"Seeking heterocyclic scaffolds as antivirals against dengue virus","volume":"240","author":"De","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2022.115279_b0570","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsps.2012.03.002","article-title":"Quinoline: A versatile heterocyclic","volume":"21","author":"Marella","year":"2013","journal-title":"Saudi Pharm J."},{"issue":"22","key":"10.1016\/j.bcp.2022.115279_b0575","doi-asserted-by":"crossref","first-page":"10228","DOI":"10.1021\/acs.jmedchem.8b01394","article-title":"Discovery of Benzoazepinequinoline (BAQ) Derivatives as Novel, Potent, Orally Bioavailable Respiratory Syncytial Virus Fusion Inhibitors","volume":"61","author":"Zheng","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2022.115279_b0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112706","article-title":"Design, synthesis and in vitro anti-influenza A virus evaluation of novel quinazoline derivatives containing S-acetamide and NH-acetamide moieties at C-4","volume":"206","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2022.115279_b0585","doi-asserted-by":"crossref","first-page":"11861","DOI":"10.3390\/molecules200711861","article-title":"Synthesis, Antiviral Bioactivity of Novel 4-Thioquinazoline Derivatives Containing Chalcone Moiety","volume":"20","author":"Wan","year":"2015","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"6","key":"10.1016\/j.bcp.2022.115279_b0590","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1021\/acsinfecdis.1c00083","article-title":"Quinoline and Quinazoline Derivatives Inhibit Viral RNA Synthesis by SARS-CoV-2 RdRp","volume":"7","author":"Zhao","year":"2021","journal-title":"ACS Infect Dis."},{"key":"10.1016\/j.bcp.2022.115279_b0595","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.biopha.2018.01.030","article-title":"Corilagin, a promising medicinal herbal agent","volume":"99","author":"Li","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.bcp.2022.115279_b0600","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.apsb.2021.02.011","article-title":"Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase","volume":"11","author":"Li","year":"2021","journal-title":"Acta Pharmaceutica Sinica. B"},{"key":"10.1016\/j.bcp.2022.115279_b0605","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.antiviral.2017.12.004","article-title":"A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage","volume":"150","author":"Reddy","year":"2018","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2022.115279_b0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153591","article-title":"Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding","volume":"87","author":"Yang","year":"2021","journal-title":"Phytomedicine."},{"key":"10.1016\/j.bcp.2022.115279_b0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154266","article-title":"Lycorine and organ protection: Review of its potential effects and molecular mechanisms","volume":"104","author":"Xiao","year":"2022","journal-title":"Phytomedicine."},{"issue":"12","key":"10.1016\/j.bcp.2022.115279_b0620","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00023-19","article-title":"High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses","volume":"93","author":"Shen","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2022.115279_b0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.197989","article-title":"Natural product-derived phytochemicals as potential agents against coronaviruses: A review","volume":"284","author":"Mani","year":"2020","journal-title":"Virus Res."},{"issue":"1","key":"10.1016\/j.bcp.2022.115279_b0630","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1080\/22221751.2020.1772676","article-title":"Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture","volume":"9","author":"Zhang","year":"2020","journal-title":"Emerg. Microbes Infect."},{"issue":"2","key":"10.1016\/j.bcp.2022.115279_b0635","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/s41401-021-00668-7","article-title":"A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors","volume":"43","author":"Ren","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bcp.2022.115279_b0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153440","article-title":"Lycorine, a non-nucleoside RNA dependent RNA polymerase inhibitor, as potential treatment for emerging coronavirus infections","volume":"86","author":"Jin","year":"2021","journal-title":"Phytomedicine."},{"issue":"18","key":"10.1016\/j.bcp.2022.115279_b0645","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s11434-016-1136-5","article-title":"the golden herb from the garden of Chinese medicinal plants","volume":"61","author":"Zhao","year":"2016","journal-title":"Sci. Bull. (Beijing)."},{"issue":"1","key":"10.1016\/j.bcp.2022.115279_b0650","doi-asserted-by":"crossref","first-page":"21221","DOI":"10.1038\/s41598-021-98949-y","article-title":"Antiviral activity of silymarin and baicalein against dengue virus","volume":"11","author":"Low","year":"2021","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.bcp.2022.115279_b0655","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00705-018-4083-4","article-title":"Baicalein and baicalin as Zika virus inhibitors","volume":"164","author":"Oo","year":"2019","journal-title":"Arch. Virol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115279_b0660","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1248\/bpb.33.238","article-title":"Inhibitory effects of baicalein on the influenza virus in vivo is determined by baicalin in the serum","volume":"33","author":"Xu","year":"2010","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.bcp.2022.115279_b0665","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jep.2014.08.031","article-title":"Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects","volume":"156","author":"Li","year":"2014","journal-title":"J. Ethnopharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2022.115279_b0670","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40261-016-0418-7","article-title":"Multiple-Ascending-Dose Pharmacokinetics and Safety Evaluation of Baicalein Chewable Tablets in Healthy Chinese Volunteers","volume":"36","author":"Pang","year":"2016","journal-title":"Clin. Drug Investig."},{"issue":"1","key":"10.1016\/j.bcp.2022.115279_b0675","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/14756366.2021.1873977","article-title":"extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease","volume":"36","author":"Liu","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bcp.2022.115279_b0680","doi-asserted-by":"crossref","unstructured":"S. Huang, Y.e. Liu, Y. Zhang, R. Zhang, C. Zhu, L. Fan, et al., Baicalein inhibits SARS-CoV-2\/VSV replication with interfering mitochondrial oxidative phosphorylation in a mPTP dependent manner, Signal Transduction Targeted Ther. 5(1) (2020) 266.","DOI":"10.1038\/s41392-020-00353-x"},{"key":"10.1016\/j.bcp.2022.115279_b0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114302","article-title":"The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro","volume":"183","author":"Song","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2022.115279_b0690","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3390\/microorganisms9050893","article-title":"Baicalein and Baicalin Inhibit SARS-CoV-2 RNA-Dependent-RNA Polymerase","volume":"9","author":"Zandi","year":"2021","journal-title":"Microorganisms"},{"issue":"7889","key":"10.1016\/j.bcp.2022.115279_b0695","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/d41586-021-03672-3","article-title":"Omicron likely to weaken COVID vaccine protection","volume":"600","author":"Callaway","year":"2021","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.bcp.2022.115279_b0700","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"10317","key":"10.1016\/j.bcp.2022.115279_b0705","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/S0140-6736(21)02758-6","article-title":"Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic","volume":"398","author":"Karim","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"10325","key":"10.1016\/j.bcp.2022.115279_b0710","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0140-6736(22)00090-3","article-title":"Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose","volume":"399","author":"Kuhlmann","year":"2022","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bcp.2022.115279_b0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105078","article-title":"A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase","volume":"190","author":"Zhao","year":"2021","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2022.115279_b0720","doi-asserted-by":"crossref","unstructured":"O.M. Ogunyemi, G.A. Gyebi, A.A. Elfiky, S.O. Afolabi, O.B. Ogunro, A.P. Adegunloye, et al., Alkaloids and flavonoids from African phytochemicals as potential inhibitors of SARS-Cov-2 RNA-dependent RNA polymerase: an perspective, Antivir. Chem. Chemother. 28 (2020) 2040206620984076.","DOI":"10.1177\/2040206620984076"},{"issue":"9","key":"10.1016\/j.bcp.2022.115279_b0725","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s00705-020-04706-3","article-title":"Antiviral activity of berberine","volume":"165","author":"Warowicka","year":"2020","journal-title":"Arch. Virol."},{"issue":"5","key":"10.1016\/j.bcp.2022.115279_b0730","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3390\/biomedicines10051170","article-title":"Natural Polyphenols, 1,2,3,4,6-O-Pentagalloyglucose and Proanthocyanidins, as Broad-Spectrum Anticoronaviral Inhibitors Targeting Mpro and RdRp of SARS-CoV-2","volume":"10","author":"Jin","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.bcp.2022.115279_b0735","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153286","article-title":"Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID-19: A review","volume":"85","author":"Mhatre","year":"2021","journal-title":"Phytomedicine."},{"issue":"16","key":"10.1016\/j.bcp.2022.115279_b0740","doi-asserted-by":"crossref","first-page":"6249","DOI":"10.1080\/07391102.2020.1796810","article-title":"Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibition: an analysis","volume":"39","author":"Singh","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"7","key":"10.1016\/j.bcp.2022.115279_b0745","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1002\/ptr.7486","article-title":"Comparative evaluation of flavonoids reveals the superiority and promising inhibition activity of silibinin against SARS-CoV-2","volume":"36","author":"Hamdy","year":"2022","journal-title":"Phytother Res."},{"issue":"1","key":"10.1016\/j.bcp.2022.115279_b0750","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2174\/0929867328666210820114025","article-title":"Cordycepin as a Promising Inhibitor of SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp)","volume":"29","author":"Bibi","year":"2022","journal-title":"Curr. Med. Chem."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222003732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222003732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:15:07Z","timestamp":1762096507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295222003732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":150,"alternative-id":["S0006295222003732"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2022.115279","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2022.115279","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115279"}}